Clinical outcomes of concomitant use of proton pump inhibitors and regorafenib in patients with metastatic colorectal cancer: a multicenter study

CONCLUSION: This study found no worse outcome in the combined use of PPI and regorafenib among patients with mCRC.PMID:36266366 | DOI:10.1007/s00228-022-03403-1

Source: Clinical Colorectal Cancer - October 20, 2022 Category: Cancer & Oncology Authors: Emre Yeked üz Mehmet Fatih Özbay Dilek Çağlayan Atila Y ıldırım Cihan Erol Hasan Çağrı Yıldırım Sezai Tun ç Neslihan Özyurt Feyyaz Özdemir Mehmet Ali Nahit Şendur Abdurrahman I şıkdoğan Saadettin K ılıçkap Y üksel Ürün Şuayib Ya Source Type: research